Who are Avirmax's investors?

Avirmax's investors include 3E Bioventures Capital, BioVentures.

How much funding has Avirmax raised?

Avirmax has disclosed $3M raised across 1 round.

Where is Avirmax headquartered?

Avirmax is headquartered in Hayward, US.

Avirmax

Hayward, US · Founded 2019 · Delaware corporation · 2 known investors

Avirmax is a preclinical-stage biopharmaceutical company developing AAV-based genetic medicines to treat chronic and degenerative ocular diseases. Through its Avirmax CMC (ACI) division, it also provides bioprocess development and manufacturing services for AAV-based gene therapies to external customers.

Biotech Deep Tech Medical Devices

Founders & leadership

Haifeng ChenDirector and Treasurer of the Issuer

Shengjiang LiuNamed on SEC filing

Board

Yu FangDirector of the Issuer

Qianye Karen LiuDirector of the Issuer

Nancy ChangDirector of the Issuer

Investors · 2

3E Bioventures CapitalPalo Alto

BioVenturesreportedBelmont

Reported raises · per SEC filings

Form D private placements

$3M disclosed across 1 round · 2019

▶$3MraisedNov 2019 · 10 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Yu FangDirector
Qianye Karen LiuDirector
Haifeng ChenExecutive Officer, Director
Shengjiang LiuExecutive Officer, Director
Nancy ChangDirector

Offering amount: $10M
Amount sold: $3M
First sale: Nov 2019
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

1Mg4 shared keywordsTata 1mg is India's leading online pharmacy and healthcare platform that offers medicines, lab tests, doctor consultations, and cancer care services. The company operates a digital marketplace serving Indian consumers seeking pharmaceuticals, diagnostic testing, and medical advice.

Companies competing with Avirmax for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Avirmax do?: Avirmax is a preclinical-stage biopharmaceutical company developing AAV-based genetic medicines to treat chronic and degenerative ocular diseases. Through its Avirmax CMC (ACI) division, it also provides bioprocess development and manufacturing services for AAV-based gene therapies to external customers.
Who are Avirmax's investors?: Avirmax's investors include 3E Bioventures Capital, BioVentures.
How much funding has Avirmax raised?: Avirmax has disclosed $3M raised across 1 round.
Where is Avirmax headquartered?: Avirmax is headquartered in Hayward, US.